Value Analysis Committee Strategy:
How Medical Devices Get Approved for Hospital Purchase

Your surgeon champion loves the device. She has used it, she wants it, and she has said so to her department. None of that puts you on contract. In most US health systems the purchase decision runs through a value analysis committee, a standing group that reviews new product requests against clinical evidence, cost, and operational fit before anything gets ordered.

That review has gotten harder, and the reason is arithmetic. Hospital supply expenses rose 9.9% in 2025, and total hospital expenses grew 7.5%, more than twice the rate of growth in hospital prices.¹ Median hospital operating margin sat at 3.3% through March 2026, with supply expense per adjusted discharge up 7% year over year.² A committee working inside those numbers is not looking for reasons to say yes.

Most early commercial teams prepare for the wrong meeting. They build a clinical story for a physician, then face an operational and financial question from a nurse manager, a supply chain director, and a controller who have never seen the product.

The following post breaks down who sits on the committee, the four questions it has to resolve, where device companies lose the room, and what to put in front of it.

Why the Value Analysis Committee Is the Real Buyer

A value analysis committee is a standing hospital group that reviews requests for new clinical products and decides whether they are approved for purchase. Membership varies, but the recurring seats are clinical leadership, nursing, supply chain, finance, and depending on the product, infection prevention, biomedical engineering, and IT security.

Larger systems run this in tiers. A service line committee screens the request, a system-level committee decides anything crossing facilities, and capital above a dollar threshold goes to a separate committee on its own calendar. A request that looks approved at one hospital can still be queued three levels up.

The shift is not new. A Bain survey published in 2018 found that only 17% of surgeons reported a large degree of discretion over equipment purchasing, while close to 60% of physicians said decisions were led primarily by procurement officers with some physician input.³ Consolidation since then has pushed that authority upward, not down. Your champion is a sponsor, not a signer.

What a Hospital Value Analysis Committee Actually Asks

A value analysis committee evaluates the total cost of adoption, not the price of your device. Four questions sit underneath every review.

1. Does This Replace Something, Add to Something, or Create a New Line Item?

Substitution is the easiest case, because the committee can compare against a known spend. Addition is harder, since it needs new money. A new category is hardest, because no budget line is waiting for it and someone has to create one.

2. What Does It Cost Per Case, Fully Loaded?

Unit price is the starting number, not the answer. The committee adds disposables, capital, service contracts, training hours, storage, waste, and the cost of anything the device makes unnecessary. Bring that arithmetic yourself, or they will build it without you.

3. Who Gets Paid, and How?

The committee needs to know which code the procedure bills under, whether regional payers cover it, and what the facility actually collects. A weak reimbursement position becomes visible here, which is why coding, coverage, and payment belong in the launch plan.

4. What Breaks When We Adopt It?

Every new product has an operational tail: reprocessing, EHR integration, security review for anything connected, credentialing for your field team, storage, and training time pulled from a short staffed unit. Committees reject workable products over unanswered operational questions more often than over price.

Where the Medical Device Hospital Purchasing Process Breaks Down

The champion submits the request alone. A physician filling out a product request form at 9pm writes two sentences about clinical preference, and that becomes the committee's first impression of your device. Co-write it.

The economics are a claim, not a model. "Reduces length of stay" is a marketing sentence. A budget impact model built on that hospital's own volumes, payer mix, and current costs is an argument. One of those survives a finance review.

The comparator is wrong. Companies benchmark against doing nothing. Committees benchmark against what the hospital already buys, at an incumbent contract price they are not going to show you. Name the comparator before they do.

Nobody asked what the format is. Most systems have a required template, a meeting calendar, and a materials deadline. Asking supply chain for all three is a five minute conversation that routinely saves a quarter.

A successful trial gets mistaken for a win. Evaluations are cheap for the hospital and expensive for you. An eval that ends without contract terms, a volume commitment, and a named next step is a stall wearing the costume of progress.

Building a Value Analysis Dossier That Survives the Room

Here is the part most companies skip. In nearly every review, your materials are discussed when you are not in the room. The dossier has to be legible to someone who missed the demo and has to answer the objection raised after you leave. Building it is operational work, not a design exercise. Six pieces carry it.

1. A one-page clinical summary for a non-specialist. Name the comparator, state the population, and be precise about what clearance establishes. A 510(k) means substantial equivalence to a predicate, not proven superiority, and saying so plainly earns more credibility than overclaiming.
2. A budget impact model with editable assumptions. Give them a file they can change. A model the finance seat can re-run with its own volumes turns a sales claim into a shared calculation.
3. A coding and payment sheet. Which code, which site of service, what the facility collects, and where coverage is still open.
4. An operational impact page. Training hours by role, storage, reprocessing steps, IT security review status, and EHR touchpoints.
5. An implementation plan. Who trains whom, over what period, and which metrics get reviewed at 90 days.
6. Named references at comparable institutions. Similar size, similar case mix, willing to take a call. This is where a KOL engagement program pays out, because the reference has to already exist when the committee asks.

Sequencing matters as much as content. Assemble the dossier before you request the meeting, since a request for missing materials costs a full cycle.

The Site of Care Is Moving, and So Is the Committee

Where your device gets used is changing, which changes who reviews it. In the CY 2026 OPPS and ASC final rule, CMS added 560 procedures to the ASC covered procedures list and removed 285 mostly musculoskeletal procedures from the inpatient-only list, starting a three-year phase-out of that list.⁴

Ambulatory surgery centers buy on different terms. The committee is smaller, sometimes an administrator and a physician owner, and a decision can come in weeks rather than quarters. It is less forgiving on per-case cost, because the facility fee is fixed and the owners feel the margin directly. If your procedure is on that migration list, build a second version of the dossier around ASC economics. The clinical summary carries over. The cost model does not.

Frequently Asked Questions About Value Analysis Committees

Getting a Decision Instead of a Deferral

The value analysis committee is not an obstacle between you and the sale. It is the sale. A clinical champion tells you the product works. The committee tells you whether the institution can afford to run it, staff it, bill for it, and support it. Only one of those ends in a purchase order.

Treat the committee as a named account with its own buying process. Learn its calendar, its template, and its comparator, then build the economic case in its numbers instead of yours. Ask for a decision with a date attached, because a request that never gets voted on is the most common way a cleared device quietly fails to launch.

Related reading: Coverage, Coding, and Payment: Why Reimbursement Strategy Belongs in Your Launch Plan